Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition
Respir Investig. 2024 Mar 13;62(3):402-418. doi: 10.1016/j.resinv.2024.02.014. Online ahead of print.ABSTRACTIdiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with a poor prognosis and an unknown cause that generally progresses to pulmonary fibrosis and leads to irreversible tissue alteration. The "Guidelines for the treatment of idiopathic pulmonary fibrosis 2017," specializing in the treatment of IPF for the first time in Japan and presenting evidence-based standard treatment methods suited to the state of affairs in Japan, was published in 2017, in line with the 2014 version of "Formulation procedure f...
Source: Respiratory Care - March 14, 2024 Category: Respiratory Medicine Authors: Masashi Bando Sakae Homma Hiroshi Date Kazuma Kishi Hiroyoshi Yamauchi Susumu Sakamoto Atsushi Miyamoto Yoshihito Goto Takeo Nakayama Arata Azuma Yasuhiro Kondoh Takeshi Johkoh Yasuhiko Nishioka Junya Fukuoka Yasunari Miyazaki Ichiro Yoshino Takafumi Suda Source Type: research
Clinical and Genetic Spectrum of Nine Cases of NLRP3-Associated Autoinflammatory Disease (NLRP3-AID) and Identification of One Novel NLRP3 Mutation by Genetic Variation Analyses
CONCLUSIONS: Our study illuminated the distinct clinical and genetic features of Chinese NLRP3-AID patients, emphasizing the significance of early genetic screening. Despite delayed diagnosis, treatment primarily with glucocorticoids and biologic agents, led to favorable outcomes. Genetic heterogeneity, including a novel mutation, highlighted the complexity of NLRP3-AID in this population.PMID:38481988 | PMC:PMC10937081 | DOI:10.1155/2024/5722548 (Source: Journal of Immunology Research)
Source: Journal of Immunology Research - March 14, 2024 Category: Allergy & Immunology Authors: Yaoyao Shangguan Xingru Ding Le Ma Yi-Xin Cai Shulei Xiang Xiu-Feng Huang Yunyan Shen Hai-Guo Yu Wenjie Zheng Source Type: research
Respiratory infection risk in primary Sj ögren’s syndrome complicated with interstitial lung disease: a retrospective study
(Source: Clinical Rheumatology)
Source: Clinical Rheumatology - March 14, 2024 Category: Rheumatology Source Type: research
Risk factors for critical COVID-19 illness during Delta- and Omicron-predominant period in Korea; using K-COV-N cohort in the National health insurance service
ConclusionWe found that the severity of COVID-19 infection was much higher for the Delta variant than for the Omicron. Although the Delta and the Omicron variant shared many risk factors for critical illness, several risk factors were found to have different effects on the development of critical COVID-19 illness between those two variants. Close monitoring of a wide range of risk factors for critical illness is warranted as new variants continue to emerge during the pandemic. (Source: PLoS One)
Source: PLoS One - March 14, 2024 Category: Biomedical Science Authors: Kyung-Shin Lee Source Type: research
Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment
Semin Respir Crit Care Med DOI: 10.1055/s-0044-1782218Interstitial lung disease (ILD) is a common pulmonary complication of rheumatoid arthritis (RA), causing significant morbidity and mortality. Optimal treatment for RA-ILD is not yet well defined. Reliable prognostic indicators are largely byproducts of prior ILD progression, including low or decreasing forced vital capacity and extensive or worsening fibrosis on imaging. In the absence of validated tools to predict treatment response, decisions about whether to initiate or augment treatment are instead based on clinical judgment. In general, treatment should be initiate...
Source: Seminars in Respiratory and Critical Care Medicine - March 14, 2024 Category: Respiratory Medicine Authors: Pugashetti, Janelle Vu Lee, Joyce S. Tags: Review Article Source Type: research
